Ulcerative Colitis Market: How Are IL-23 Inhibitors Reshaping the...

adicionou um novo artigo Health

2026-07-04 09:36:42 -

Ulcerative Colitis Market: How Are IL-23 Inhibitors Reshaping the Treatment Paradigm for Moderate-to-Severe Disease?

IL-23 inhibitors in ulcerative colitis — the selective biologics targeting the p19 subunit of interleukin-23 (mirikizumab, risankizumab, guselkumab) demonstrating superior efficacy and safety profiles in head-to-head trials representing the fastest-growing drug class — create the most clinically differentiated market opportunity, with the Ulcerative Colitis Market reflecting IL-23...

0 Comentários 0 Compartilhamentos 11 Visualizações 0 Anterior